Breast Cancer
Conditions
Keywords
Breast cancer, Elderly, Chemotherapy, Cardiotoxicity
Brief summary
This study will evaluate the efficacy, safety and effect on quality of life of liposomal-encapsulated doxorubicin in combination with cyclophosphamide as first or second line treatment of older patients (≥ 70 years old) with metastatic breast cancer. The efficacy of the combination will be correlated with the functional status of patients according to the comprehensive geriatric assessment
Detailed description
Elderly individuals make up a large part of the breast cancer population. When treated with chemotherapy for metastatic disease they derive similar benefits to their younger counterparts. Anthracyclines are associated with a cumulative dose-dependent cardiomyopathy with increased rate in patients over the age of 70. Liposomal-encapsulated doxorubicin improves the therapeutic index of doxorubicin by reducing significantly the cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for metastatic breast cancer
Interventions
DRUGCyclophosphamide
Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy. Therapy will continue until maximum response,or unacceptable toxicity.
DRUGLiposomal-encapsulated doxorubicin
Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy. Therapy will continue until maximum response or unacceptable toxicity.
Sponsors
Hellenic Oncology Research Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed metastatic breast adenocarcinoma * No more than one prior therapy regimen (other than hormonal therapy) for metastatic breast cancer is acceptable. * Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions) * Performance status (WHO) 0-2 * Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases) * Adequate renal function (serum creatinine \<1.5 times the upper normal limit) * Adequate cardiac function (LVEF within normal limits) * Adequate bone marrow function (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) * No radiation of measurable disease (except brain metastases) * No progressive brain metastases according to clinical or radiological criteria * No brain metastases without prior radiation therapy * Written informed consent
Exclusion criteria
* Active infection * History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) * Prior treatment with an anthracycline-containing regimen (as adjuvant therapy) during the previous 12 months period * Other invasive malignancy except non-melanoma skin cancer * Psychiatric illness or social situation that would preclude study compliance * Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate | Objective responses confirmed by CT or MRI every 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Toxicity profile | Toxicity assessment every month |
| Time to Tumor Progression | 1-year |
| Overall Survival | 1 year |
Countries
Greece
Outcome results
None listed